Evaxion Biotech A/S (NASDAQ:EVAX) Upgraded to Buy at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAXFree Report) from a neutral rating to a buy rating in a report issued on Tuesday morning, MarketBeat.com reports. The firm currently has $8.00 target price on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $14.00 price target on shares of Evaxion Biotech A/S in a report on Wednesday, March 20th.

Read Our Latest Report on Evaxion Biotech A/S

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ EVAX opened at $3.88 on Tuesday. The business’s 50 day moving average price is $4.01 and its 200-day moving average price is $6.45. Evaxion Biotech A/S has a fifty-two week low of $2.82 and a fifty-two week high of $18.50. The company has a market cap of $15.71 million, a price-to-earnings ratio of -0.57 and a beta of -0.02.

Hedge Funds Weigh In On Evaxion Biotech A/S

Institutional investors have recently modified their holdings of the stock. LM Advisors LLC purchased a new position in shares of Evaxion Biotech A/S in the 4th quarter valued at about $231,000. Beacon Capital Management LLC lifted its holdings in Evaxion Biotech A/S by 606.8% in the fourth quarter. Beacon Capital Management LLC now owns 48,633 shares of the company’s stock valued at $33,000 after acquiring an additional 41,752 shares during the last quarter. AE Wealth Management LLC acquired a new position in Evaxion Biotech A/S during the third quarter worth $41,000. JPMorgan Chase & Co. purchased a new stake in shares of Evaxion Biotech A/S during the second quarter worth $38,000. Finally, Susquehanna International Group LLP increased its holdings in Evaxion Biotech A/S by 185.4% in the first quarter. Susquehanna International Group LLP now owns 118,722 shares of the company’s stock valued at $134,000 after buying an additional 77,122 shares during the last quarter. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

See Also

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.